Senti Bio License for Development and Commercialization of Next Generation Chimeric Antigen Receptor (CAR) Therapies for the Treatment of FMS-Like tyrosine kinase 3 (FLT3) Expressing Cancers

On April 19, 2019, HealthGap, Knowledge Ecology International, Public Citizen, Social Security Works and the Union for Affordable Cancer Treatment filed comments on a proposed license on National Cancer Institute patented inventions to Senti Bio, for a next generation CAR… Continue Reading

KEI Comments Regarding the NIST Special Publication 1234 Draft Green Paper on Return on Public Investment

KEI filed comments on the NIST Draft Green paper on the return from investment on federally funded R&D (See: https://www.keionline.org/29518). We expect the comment period to be extended, but filed this on January 9, 2018, as an initial submission. KEI-comments-NIST-SP-1234-ROI-9Jan2018… Continue Reading

2018: KEI comments on Navy proposed exclusive license to Vedevo for data compression patent

Office of Research and Technology Applications, Naval Postgraduate School, Research and Sponsored Programs Office, NPS Code 41, 699 Dyer Road, Bldg. HA, Room 226, Via. Ms. Deborah Buettner, Director, Research and Sponsored Programs Office, email: dbuettne@nps.edu Dear Deborah Beuttner, We… Continue Reading

2018: Comments on NIH license to Bull Run Capital, Inc. for safer non-lethal antagonist

Jaime M. Greene Senior Licensing and Patenting Manager NCI Technology Transfer Center Email: greenejaime@mail.nih.gov December 16, 2018 Re: Comments on “Prospective Grant of an Exclusive Patent License: Agonist/Antagonist Compositions and Methods of Use for certain inventions” (83 FR 61659) Dear… Continue Reading